Details for Patent: 9,814,721
✉ Email this page to a colleague
Title: | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Abstract: | Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. |
Inventor(s): | Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA) |
Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
Filing Date: | Mar 10, 2016 |
Application Number: | 15/066,491 |
Claims: | 1. A method for treating marginal zone lymphoma (MZL) in an individual in need thereof, wherein the individual has received at least one prior anti-CD20-based therapy, comprising: administering to the individual once per day about 560 mg of an oral dose of a compound having the structure: ##STR00046## 2. The method of claim 1, wherein the MZL is relapsed or refractory MZL. 3. The method of claim 1, wherein the MZL is extranodal marginal zone B cell lymphoma. 4. The method of claim 1, wherein the MZL is extranodal marginal zone B-cell lymphoma-mucosa-associated lymphoid tissue (MALT) lymphoma. 5. The method of claim 1, wherein the MZL is nodal marginal zone B-cell lymphoma. 6. The method of claim 1, wherein the MZL is splenic marginal zone B-cell lymphoma. 7. The method of claim 1, wherein the compound is in the form of a solid oral dosage form. 8. The method of claim 1, wherein, following administration of the compound, the individual achieves a stable disease, a partial response, or a complete response. 9. The method of claim 1, wherein, following administration of the compound, the individual achieves a partial response or a complete response. 10. The method of claim 1, wherein, following administration of the compound, the individual achieves a complete response. 11. The method of claim 1, wherein, following administration of the compound, the individual does not experience a progressive disease. |